Preoperative Ultrasound Guided Thoracic Erector Spinae Plane Block Versus Costoclavicular Block for Shoulder Arthroscopy

NCT06913140 | Completed

• 1 other identifier: 35844/9/22
• Study Type: interventional
• Target: 90
• Locations: 1 country
• Sites: 1

Brief Summary

This study was conducted to compare the perioperative analgesic effect of ultrasound guided high thoracic erector spinae plane block versus ultrasound guided costoclavicular block for shoulder arthroscopy

Conditions

Preoperative; Ultrasound; Thoracic Erector Spinae Plane Block; Costoclavicular Block; Shoulder Arthroscopy

Outcome Measures

Primary Outcomes (1)

• Total Pethidine consumption

  Each patient was instructed about postoperative pain assessment with the Visual Analogue Scale (VAS). VAS (0 represents "no pain" while 10 represents "the worst pain imaginable") at (T 30 min, 2, 4, 6,12, 18, 24 h, non-steroidal anti-inflammatory drugs were given (ketorolac 30mg) to all patient /8 h and if VAS \> 4 intravenous pethidine 0.5 mg / kg per dose.

  24 hours postoperatively

Secondary Outcomes (3)

• Time to first analgesic request after surgery

  24 hours postoperatively

• Degree of pain

  24 hours postoperatively

• Complications

  24 hours postoperatively

Study Arms (3)

Erector Spinae plane Block group

EXPERIMENTAL

Patients received (20ml) plain bupivacaine 0.25% injected beneath the erector spinae muscle sheath at the level of the second thoracic segment (T2)

Drug: Erector Spinae plane Block

Costoclavicular block group

EXPERIMENTAL

Patients received (20ml) plain bupivacaine 0.25% injected in the costoclavicular space lateral to axillary artery

Drug: Costoclavicular block

Control group

SHAM COMPARATOR

Patients received sham block .

Drug: Control group

Interventions

Erector Spinae plane Block DRUG

Patients received (20ml) plain bupivacaine 0.25% injected beneath the erector spinae muscle sheath at the level of the second thoracic segment (T2)

Also known as: Bupivacaine 0.25%

Erector Spinae plane Block group

Costoclavicular block DRUG

Patients received (20ml) plain bupivacaine 0.25% injected in the costoclavicular space lateral to axillary artery.

Also known as: Bupivacaine 0.25%

Costoclavicular block group

Control group DRUG

Patients received sham block

Also known as: Sham block

Control group

Eligibility Criteria

• Age: 21 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• patients admitted for elective unilateral shoulder arthroscopy.
• Aged (21 - 65) years.
• American Society of Anesthesiologists (ASA) physical activity I, II

You may not qualify if:

• Patient refusal.
• Patient with neurological deficit.
• Patient with bleeding disorders (coagulopathy, thrombocytopenia anticoagulant and antiplatelets drugs).
• Uncooperative patient.
• Infection at the block injection site.
• Patients with history of allergy to local anaesthetics

Sponsors & Collaborators

• Tanta University: lead

Study Sites (1)

Tanta University

Tanta, El-Gharbia, 31527, Egypt

Location

MeSH Terms

Interventions

Control Groups

Intervention Hierarchy (Ancestors)

Epidemiologic Research Design; Epidemiologic Methods; Investigative Techniques; Research Design; Methods

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Lecturer of Anesthesiology, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt.

Study Record Dates

• First Submitted: March 29, 2025
• First Posted: April 6, 2025
• Study Start: December 1, 2022
• Primary Completion: November 1, 2024
• Study Completion: November 1, 2024
• Last Updated: April 25, 2025

Record last verified: 2025-04

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL
• Time Frame: After the end of study for one year.
• Access Criteria: The data will be available upon a reasonable request from the corresponding author

Locations

EG (1)